MK-2866 and Naltrexone Interaction
MK-2866 and Naltrexone have a potentially harmful interaction with 64% confidence. Both MK-2866 and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.
Compound Profiles
MK-2866
Selective Androgen Receptor Modulator | Muscle Wasting Research
MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.
View full profileNaltrexone
Opioid Antagonist | Low-Dose Anti-Inflammatory & Immune Modulation
At low doses (1-4.5 mg), naltrexone produces a brief nocturnal blockade of opioid receptors that lasts approximately 4-6 hours.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take MK-2866 with Naltrexone?
Combining MK-2866 with Naltrexone is not recommended. Both MK-2866 and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is MK-2866 and Naltrexone safe together?
This combination carries significant risk. Both MK-2866 and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between MK-2866 and Naltrexone?
Both MK-2866 and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.
How should I time MK-2866 and Naltrexone?
MK-2866 has a half-life of ~24 hours and Naltrexone has a half-life of ~4 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.